Hailang He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hailang He has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Xianmei Zhou
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
19 shared publications Fanchao Feng
Department of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
7 shared publicationsYong Xu
School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China
7 shared publicationsZhichao Wang
Department of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
7 shared publicationsDi Han
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
6 shared publicationsWenpan Peng
Department of Pulmonary and Critical Care Medicine, Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Suzhou, China
6 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e89891
Efficacy and Safety of Kanggan Mixture for Influenza: Protocol for a Multicenter Open-Label Randomized Controlled Trial
Background: Influenza, a highly contagious acute respiratory illness, causes annual seasonal epidemics worldwide, imposing a substantial public health burden. Although neuraminidase inhibitors, such as oseltamivir, can shorten symptom duration, their use is limited by antiviral resistance and adverse reactions. Kanggan mixture (KGM), an in-hospital traditional Chinese medicine preparation at Jiangsu Province Hospital of Chinese Medicine, has been widely used in clinical practice for influenza treatment, showing favorable effects on fever reduction and symptom improvement; however, high-quality comparative evidence on the efficacy and safety of KGM remains limited. This study is designed to address this gap by evaluating whether KGM is noninferior to oseltamivir for the treatment of influenza. Objective: This study aims to determine whether KGM is noninferior to oseltamivir in improving the clinical outcomes in patients with influenza and to assess the safety profile of KGM. Methods: This study is a multicenter, open-label, randomized controlled trial to be conducted in 3 tertiary grade A hospitals in China. Eligible participants with influenza will be randomly assigned in a 1:1 ratio to receive either KGM or oseltamivir for 5 days. A total of 184 participants will be enrolled, with 92 (50%) participants in each group. The primary outcome is time to clinical alleviation. Secondary outcomes include time to defervescence, time to onset of antipyretic effect, individual influenza symptom scores, and total influenza symptom scores. Adverse events will be monitored throughout the trial to evaluate the safety of KGM. Results: This study was funded in July 2024. Recruitment began in September 2025 and is expected to be completed in June 2026. The study results are expected to be published by December 2026. Conclusions: This protocol describes a multicenter randomized controlled trial designed to generate comparative evidence on the efficacy and safety of KGM for influenza treatment. The findings of this study are expected to provide initial clinical evidence supporting the use of KGM in the treatment of influenza, clarify its therapeutic value as a potential alternative to oseltamivir, and offer a novel alternative strategy for influenza management while contributing to the evidence base for integrating traditional Chinese medicine into influenza care. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000743; https://itmctr.ccebtcm.org.cn/mgt/project/view/-5368318132552339899 International Registered Report Identifier (IRRID): DERR1-10.2196/89891
- 2 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e89891
Open AccessEfficacy and Safety of Kanggan Mixture for Influenza: Protocol for a Multicenter Open-Label Randomized Controlled Trial
Background: Influenza, a highly contagious acute respiratory illness, causes annual seasonal epidemics worldwide, imposing a substantial public health burden. Although neuraminidase inhibitors, such as oseltamivir, can shorten symptom duration, their use is limited by antiviral resistance and adverse reactions. Kanggan mixture (KGM), an in-hospital traditional Chinese medicine preparation at Jiangsu Province Hospital of Chinese Medicine, has been widely used in clinical practice for influenza treatment, showing favorable effects on fever reduction and symptom improvement; however, high-quality comparative evidence on the efficacy and safety of KGM remains limited. This study is designed to address this gap by evaluating whether KGM is noninferior to oseltamivir for the treatment of influenza. Objective: This study aims to determine whether KGM is noninferior to oseltamivir in improving the clinical outcomes in patients with influenza and to assess the safety profile of KGM. Methods: This study is a multicenter, open-label, randomized controlled trial to be conducted in 3 tertiary grade A hospitals in China. Eligible participants with influenza will be randomly assigned in a 1:1 ratio to receive either KGM or oseltamivir for 5 days. A total of 184 participants will be enrolled, with 92 (50%) participants in each group. The primary outcome is time to clinical alleviation. Secondary outcomes include time to defervescence, time to onset of antipyretic effect, individual influenza symptom scores, and total influenza symptom scores. Adverse events will be monitored throughout the trial to evaluate the safety of KGM. Results: This study was funded in July 2024. Recruitment began in September 2025 and is expected to be completed in June 2026. The study results are expected to be published by December 2026. Conclusions: This protocol describes a multicenter randomized controlled trial designed to generate comparative evidence on the efficacy and safety of KGM for influenza treatment. The findings of this study are expected to provide initial clinical evidence supporting the use of KGM in the treatment of influenza, clarify its therapeutic value as a potential alternative to oseltamivir, and offer a novel alternative strategy for influenza management while contributing to the evidence base for integrating traditional Chinese medicine into influenza care. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000743; https://itmctr.ccebtcm.org.cn/mgt/project/view/-5368318132552339899 International Registered Report Identifier (IRRID): DERR1-10.2196/89891
- 21 January 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198  (4) , 2583-2606
Exploration of Mechanisms of Keliu Pill on the Inhibition of Lymphangiogenesis in Non-small Cell Lung Cancer Based on Network Pharmacology and Experimental Validation
Keliu Pill (KLW) is a Chinese medicine formula that has been shown to be effective in treating non-small cell lung cancer (NSCLC) patients. However, the potential molecular mechanism remains unclear. To explore the underlying mechanism of Keliu Pill (KLW) in treating NSCLC, the network pharmacology was applied to explore the potential mechanism of KLW in the treatment of lung cancer. With oral bioavailability (OB) ≥ 30% and drug-like index (DL) ≥ 0.18 as the filter criteria, the compounds of 6 traditional Chinese medicines (TCMs) from KLW were retrieved on Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP) and supplemented by Traditional Chinese Medicine Comprehensive Database (TCMID). The potential targets corresponding to the active components of the TCMs mentioned above were obtained from TCMSP. Subsequently, the potential underlying action mechanisms of KLW on NSCLC predicted by the network pharmacology analyses were experimentally validated in Lewis lung cancer cell inoculation mice models and co-culture models with Lewis lung cancer cell and tumor-associated macrophages (TAMs). After database search and screening, a total of 20 active ingredients of Astragalus Membranaceus, 21 of Sophare Tonkinensis Radix et Rhizoma, 1 of Mylabris, 3 of Eupolyphaga, 1 of Leech, and 3 of Gecko were obtained. After deleting duplicates, 49 active ingredients were obtained. Thirty important active ingredients in KLW were sorted out by referring to relevant literature. The KEGG pathway enrichment analysis based on the DAVID platform showed that the VEGF-C signaling pathway may be the core signaling pathway associated with KLW in the treatment of NSCLC. The network pharmacological analysis demonstrated that the various components of KLW acted on NSCLC through 29 potential targets such as VEGF-C, VEGF-D, MAPK8, MAPK1, and AKT1. The experiments in vivo indicated KLW could inhibit the transcription and translation of VEGF-C and VEGF-D in tumor tissues. KLW could reduce the proportion of activated TAMs in the tissue. KLW-contained serum may decrease the expression level of VEGF-C and VEGF-D and inhibit the lymphatic lumen formation of human lymphatic endothelial cells. VEGFC and VEGFD were confirmed as the potential KLW-associated targets for NSCLC. KLW may inhibit lymphatic angiogenesis of lung cancer by regulating the function of TAMs.
- 21 January 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198  (4) , 2583-2606
Exploration of Mechanisms of Keliu Pill on the Inhibition of Lymphangiogenesis in Non-small Cell Lung Cancer Based on Network Pharmacology and Experimental Validation
Keliu Pill (KLW) is a Chinese medicine formula that has been shown to be effective in treating non-small cell lung cancer (NSCLC) patients. However, the potential molecular mechanism remains unclear. To explore the underlying mechanism of Keliu Pill (KLW) in treating NSCLC, the network pharmacology was applied to explore the potential mechanism of KLW in the treatment of lung cancer. With oral bioavailability (OB) ≥ 30% and drug-like index (DL) ≥ 0.18 as the filter criteria, the compounds of 6 traditional Chinese medicines (TCMs) from KLW were retrieved on Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP) and supplemented by Traditional Chinese Medicine Comprehensive Database (TCMID). The potential targets corresponding to the active components of the TCMs mentioned above were obtained from TCMSP. Subsequently, the potential underlying action mechanisms of KLW on NSCLC predicted by the network pharmacology analyses were experimentally validated in Lewis lung cancer cell inoculation mice models and co-culture models with Lewis lung cancer cell and tumor-associated macrophages (TAMs). After database search and screening, a total of 20 active ingredients of Astragalus Membranaceus, 21 of Sophare Tonkinensis Radix et Rhizoma, 1 of Mylabris, 3 of Eupolyphaga, 1 of Leech, and 3 of Gecko were obtained. After deleting duplicates, 49 active ingredients were obtained. Thirty important active ingredients in KLW were sorted out by referring to relevant literature. The KEGG pathway enrichment analysis based on the DAVID platform showed that the VEGF-C signaling pathway may be the core signaling pathway associated with KLW in the treatment of NSCLC. The network pharmacological analysis demonstrated that the various components of KLW acted on NSCLC through 29 potential targets such as VEGF-C, VEGF-D, MAPK8, MAPK1, and AKT1. The experiments in vivo indicated KLW could inhibit the transcription and translation of VEGF-C and VEGF-D in tumor tissues. KLW could reduce the proportion of activated TAMs in the tissue. KLW-contained serum may decrease the expression level of VEGF-C and VEGF-D and inhibit the lymphatic lumen formation of human lymphatic endothelial cells. VEGFC and VEGFD were confirmed as the potential KLW-associated targets for NSCLC. KLW may inhibit lymphatic angiogenesis of lung cancer by regulating the function of TAMs.
- Open Access
- 18 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy and Safety of Kanggan Mixture for Influenza: Protocol for a Multicenter Open-Label Randomized Controlled Trial (Preprint)
BACKGROUND Influenza, a highly contagious acute respiratory illness, causes annual seasonal epidemics worldwide, imposing a substantial public health burden. Although neuraminidase inhibitors, such as oseltamivir, can shorten symptom duration, their use is limited by antiviral resistance and adverse reactions. Kanggan mixture (KGM), an in-hospital traditional Chinese medicine preparation at Jiangsu Province Hospital of Chinese Medicine, has been widely used in clinical practice for influenza treatment, showing favorable effects on fever reduction and symptom improvement; however, high-quality comparative evidence on the efficacy and safety of KGM remains limited. This study is designed to address this gap by evaluating whether KGM is noninferior to oseltamivir for the treatment of influenza. OBJECTIVE This study aims to determine whether KGM is noninferior to oseltamivir in improving the clinical outcomes in patients with influenza and to assess the safety profile of KGM. METHODS This study is a multicenter, open-label, randomized controlled trial to be conducted in 3 tertiary grade A hospitals in China. Eligible participants with influenza will be randomly assigned in a 1:1 ratio to receive either KGM or oseltamivir for 5 days. A total of 184 participants will be enrolled, with 92 (50%) participants in each group. The primary outcome is time to clinical alleviation. Secondary outcomes include time to defervescence, time to onset of antipyretic effect, individual influenza symptom scores, and total influenza symptom scores. Adverse events will be monitored throughout the trial to evaluate the safety of KGM. RESULTS This study was funded in July 2024. Recruitment began in September 2025 and is expected to be completed in June 2026. The study results are expected to be published by December 2026. CONCLUSIONS This protocol describes a multicenter randomized controlled trial designed to generate comparative evidence on the efficacy and safety of KGM for influenza treatment. The findings of this study are expected to provide initial clinical evidence supporting the use of KGM in the treatment of influenza, clarify its therapeutic value as a potential alternative to oseltamivir, and offer a novel alternative strategy for influenza management while contributing to the evidence base for integrating traditional Chinese medicine into influenza care. CLINICALTRIAL International Traditional Medicine Clinical Trial Registry ITMCTR2025000743; https://itmctr.ccebtcm.org.cn/mgt/project/view/-5368318132552339899 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/89891
- 18 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy and Safety of Kanggan Mixture for Influenza: Protocol for a Multicenter Open-Label Randomized Controlled Trial (Preprint)
BACKGROUND Influenza, a highly contagious acute respiratory illness, causes annual seasonal epidemics worldwide, imposing a substantial public health burden. Although neuraminidase inhibitors, such as oseltamivir, can shorten symptom duration, their use is limited by antiviral resistance and adverse reactions. Kanggan mixture (KGM), an in-hospital traditional Chinese medicine preparation at Jiangsu Province Hospital of Chinese Medicine, has been widely used in clinical practice for influenza treatment, showing favorable effects on fever reduction and symptom improvement; however, high-quality comparative evidence on the efficacy and safety of KGM remains limited. This study is designed to address this gap by evaluating whether KGM is noninferior to oseltamivir for the treatment of influenza. OBJECTIVE This study aims to determine whether KGM is noninferior to oseltamivir in improving the clinical outcomes in patients with influenza and to assess the safety profile of KGM. METHODS This study is a multicenter, open-label, randomized controlled trial to be conducted in 3 tertiary grade A hospitals in China. Eligible participants with influenza will be randomly assigned in a 1:1 ratio to receive either KGM or oseltamivir for 5 days. A total of 184 participants will be enrolled, with 92 (50%) participants in each group. The primary outcome is time to clinical alleviation. Secondary outcomes include time to defervescence, time to onset of antipyretic effect, individual influenza symptom scores, and total influenza symptom scores. Adverse events will be monitored throughout the trial to evaluate the safety of KGM. RESULTS This study was funded in July 2024. Recruitment began in September 2025 and is expected to be completed in June 2026. The study results are expected to be published by December 2026. CONCLUSIONS This protocol describes a multicenter randomized controlled trial designed to generate comparative evidence on the efficacy and safety of KGM for influenza treatment. The findings of this study are expected to provide initial clinical evidence supporting the use of KGM in the treatment of influenza, clarify its therapeutic value as a potential alternative to oseltamivir, and offer a novel alternative strategy for influenza management while contributing to the evidence base for integrating traditional Chinese medicine into influenza care. CLINICALTRIAL International Traditional Medicine Clinical Trial Registry ITMCTR2025000743; https://itmctr.ccebtcm.org.cn/mgt/project/view/-5368318132552339899 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/89891
- 1 October 2025
- Vol. 45  (5) , 1009-1018
Liquid chromatography-mass spectrometry-based metabolomics study of the protective mechanism of Shenji Guben decoction on chronic obstructive pulmonary disease.
To investigate the mechanisms of the effect of Shenji Guben (SJGB) decoction on chronic obstructive pulmonary disease (COPD). A murine model of COPD was established through lipopolysaccharide (LPS) nasal drops and passive smoke exposure, followed by evaluation of SJGB decoction efficacy via lung function tests and histological analysis. Non-targeted liquid chromatography-mass spectrometry (LC-MS)-based metabolomics was used to explore the mechanisms of SJGB decoction in COPD. We found that the SJGB decoction effectively reduced inflammatory cell infiltration in the airways and lungs, and improved lung function in the COPD model mice. LC-MS-based metabolomics identified 86 biomarkers in COPD models. Compared to the model group, SJGB decoction significantly altered 34 metabolites. Prostaglandin E2 and DL-Citrulline were highlighted as two representative differential metabolites. MetaboAnalyst 5.0 highlighted glycerophospholipid and riboflavin metabolisms as key pathways affected by SJGB decoction. This study evaluated the protective effect of SJGB decoction against COPD and provided insights into its potential mechanisms in COPD treatment.
- 1 October 2025
- Vol. 45  (5) , 1009-1018
Liquid chromatography-mass spectrometry-based metabolomics study of the protective mechanism of Shenji Guben decoction on chronic obstructive pulmonary disease.
To investigate the mechanisms of the effect of Shenji Guben (SJGB) decoction on chronic obstructive pulmonary disease (COPD). A murine model of COPD was established through lipopolysaccharide (LPS) nasal drops and passive smoke exposure, followed by evaluation of SJGB decoction efficacy via lung function tests and histological analysis. Non-targeted liquid chromatography-mass spectrometry (LC-MS)-based metabolomics was used to explore the mechanisms of SJGB decoction in COPD. We found that the SJGB decoction effectively reduced inflammatory cell infiltration in the airways and lungs, and improved lung function in the COPD model mice. LC-MS-based metabolomics identified 86 biomarkers in COPD models. Compared to the model group, SJGB decoction significantly altered 34 metabolites. Prostaglandin E2 and DL-Citrulline were highlighted as two representative differential metabolites. MetaboAnalyst 5.0 highlighted glycerophospholipid and riboflavin metabolisms as key pathways affected by SJGB decoction. This study evaluated the protective effect of SJGB decoction against COPD and provided insights into its potential mechanisms in COPD treatment.
- 5 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353  (Pt A) , 120363
Mechanism study and clinical observation of Jia Wei Su Zi Jiang qi formula in reducing mucus hypersecretion in patients with chronic obstructive pulmonary disease
- 5 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353  (Pt A) , 120363
Mechanism study and clinical observation of Jia Wei Su Zi Jiang qi formula in reducing mucus hypersecretion in patients with chronic obstructive pulmonary disease
- Open Access
- 7 July 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 30  (3) , 1-8
Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review
In total, >90 unique anaplastic lymphoma kinase (ALK) rearrangement fusion partners have been identified, each with a unique sensitivity to ALK tyrosine kinase inhibitors, rendering targeted therapy challenging. In the present study, the efficacy of alectinib in a patient with advanced lung adenocarcinoma harbouring a novel ALK-microtubule-associated tumour suppressor candidate 2 (MTUS2) fusion and a rare Striatin 3 (STRN3)-ALK fusion was assessed. A 20-year-old non-smoker was hospitalised with a persistent cough. Subsequent positron emission tomography/computed tomography revealed a tumour in the right lower lobe, with mediastinal, hilar, lymph node and bone metastases. Cranial magnetic resonance imaging also revealed a cerebral metastasis. Bronchoscopic biopsy revealed an adenocarcinoma in the right lower lobe nodule, resulting in a clinical stage IVB diagnosis (cT2bN3bM1c). Targeted next-generation sequencing of tissue and blood samples revealed ALK-MTUS2 and STRN3-ALK fusions. The patient was treated with alectinib as the first-line therapy and a durable partial response was achieved after 3 months, with disappearance of the brain metastases. To the best of our knowledge, the present study represents the first discovery of simultaneous ALK-MTUS2 and STRN3-ALK fusions. The clinical outcome offers potential therapeutic options for patients with rare ALK rearrangements and underscores the necessity for further research on the functions of these fusions.
- 7 July 2025
- Published by Spandidos Publications in Oncology Letters
- Vol. 30  (3) , 1-8
Open AccessAlectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review
In total, >90 unique anaplastic lymphoma kinase (ALK) rearrangement fusion partners have been identified, each with a unique sensitivity to ALK tyrosine kinase inhibitors, rendering targeted therapy challenging. In the present study, the efficacy of alectinib in a patient with advanced lung adenocarcinoma harbouring a novel ALK-microtubule-associated tumour suppressor candidate 2 (MTUS2) fusion and a rare Striatin 3 (STRN3)-ALK fusion was assessed. A 20-year-old non-smoker was hospitalised with a persistent cough. Subsequent positron emission tomography/computed tomography revealed a tumour in the right lower lobe, with mediastinal, hilar, lymph node and bone metastases. Cranial magnetic resonance imaging also revealed a cerebral metastasis. Bronchoscopic biopsy revealed an adenocarcinoma in the right lower lobe nodule, resulting in a clinical stage IVB diagnosis (cT2bN3bM1c). Targeted next-generation sequencing of tissue and blood samples revealed ALK-MTUS2 and STRN3-ALK fusions. The patient was treated with alectinib as the first-line therapy and a durable partial response was achieved after 3 months, with disappearance of the brain metastases. To the best of our knowledge, the present study represents the first discovery of simultaneous ALK-MTUS2 and STRN3-ALK fusions. The clinical outcome offers potential therapeutic options for patients with rare ALK rearrangements and underscores the necessity for further research on the functions of these fusions.
- Open Access
- 23 October 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22  (1) , 1-9
Association of systemic corticosteroid use with prognosis of patients with acute exacerbations of chronic obstructive pulmonary disease in the intensive care unit: a propensity score-matched cohort study
Systemic corticosteroid has been recommended for the treatment of severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Little is known about the use of systemic corticosteroid in patients admitted to intensive care units (ICU) since most of previous trials excluded these critically ill patients. We conducted a matched cohort study based on the Medical Information Mart in Intensive Care-IV database. Patients with AECOPD in ICUs were included. Patients in the exposure group should be intravenously administrated with methylprednisolone or treated with oral prednisone within 24 h after ICU admission. The propensity score matching and multivariable analyses were used to adjust for covariates. The primary outcome was 28-day mortality, and secondary outcomes included ICU mortality, in-hospital mortality, the duration of ICU stay, and mechanical ventilation. Subgroup analyses for the primary outcome were performed according to age, sex, type of corticosteroid, type of ICU admission, type of mechanical ventilation, and co-morbidities/complications. The entire cohort and the matched cohort included 763 and 412 patients, respectively. In the matched cohort, the use of systemic corticosteroid had no impact on 28-day mortality (OR: 1.00, 95% CI: 0.61–1.64, P = 1.000). The results kept consistent in all subgroups. Additionally, systemic corticosteroid showed no benefits on ICU mortality, in-hospital mortality, the length of ICU stay, and the duration of mechanical ventilation. The results of this study do not support routine use of systemic corticosteroid in patients with AECOPD admitted to ICUs.
- 23 October 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22  (1) , 1-9
Open AccessAssociation of systemic corticosteroid use with prognosis of patients with acute exacerbations of chronic obstructive pulmonary disease in the intensive care unit: a propensity score-matched cohort study
Systemic corticosteroid has been recommended for the treatment of severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Little is known about the use of systemic corticosteroid in patients admitted to intensive care units (ICU) since most of previous trials excluded these critically ill patients. We conducted a matched cohort study based on the Medical Information Mart in Intensive Care-IV database. Patients with AECOPD in ICUs were included. Patients in the exposure group should be intravenously administrated with methylprednisolone or treated with oral prednisone within 24 h after ICU admission. The propensity score matching and multivariable analyses were used to adjust for covariates. The primary outcome was 28-day mortality, and secondary outcomes included ICU mortality, in-hospital mortality, the duration of ICU stay, and mechanical ventilation. Subgroup analyses for the primary outcome were performed according to age, sex, type of corticosteroid, type of ICU admission, type of mechanical ventilation, and co-morbidities/complications. The entire cohort and the matched cohort included 763 and 412 patients, respectively. In the matched cohort, the use of systemic corticosteroid had no impact on 28-day mortality (OR: 1.00, 95% CI: 0.61–1.64, P = 1.000). The results kept consistent in all subgroups. Additionally, systemic corticosteroid showed no benefits on ICU mortality, in-hospital mortality, the length of ICU stay, and the duration of mechanical ventilation. The results of this study do not support routine use of systemic corticosteroid in patients with AECOPD admitted to ICUs.
- 28 December 2023
- Published by Elsevier in Respiratory Medicine
- Vol. 222, 107498
Dietary nitrate supplementation to enhance exercise capacity in patients with COPD: Evidence from a meta-analysis of randomized controlled trials and a network pharmacological analysis
- 28 December 2023
- Published by Elsevier in Respiratory Medicine
- Vol. 222, 107498
Dietary nitrate supplementation to enhance exercise capacity in patients with COPD: Evidence from a meta-analysis of randomized controlled trials and a network pharmacological analysis
- 1 November 2021
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 45, 101470
Chinese herbal medicine for symptoms of depression and anxiety in chronic obstructive pulmonary disease: A systematic review and meta-analysis
- 1 November 2021
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 45, 101470
Chinese herbal medicine for symptoms of depression and anxiety in chronic obstructive pulmonary disease: A systematic review and meta-analysis
- Open Access
- 28 September 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
LC–MS Based Metabolomics Study of the Effects of EGCG on A549 Cells
(−)-Epigallocatechin-3-gallate (EGCG) is the main bioactive catechin in green tea. The antitumor activity of EGCG has been confirmed in various types of cancer, including lung cancer. However, the precise underlying mechanisms are still largely unclear. In the present study, we investigated the metabolite changes in A549 cells induced by EGCG in vitro utilizing liquid chromatography-mass spectrometry (LC-MS)-based metabolomics. The result revealed 33 differentially expressed metabolites between untreated and 80 μM EGCG-treated A549 cells. The altered metabolites were involved in the metabolism of glucose, amino acid, nucleotide, glutathione, and vitamin. Two markedly altered pathways, including glycine, serine and threonine metabolism and alanine, aspartate and glutamate metabolism, were identified by MetaboAnalyst 5.0 metabolic pathway analysis. These results may provide potential clues for the intramolecular mechanisms of EGCG’s effect on A549 cells. Our study may contribute to future molecular mechanistic studies of EGCG and the therapeutic application of EGCG in cancer management.
- 28 September 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessLC–MS Based Metabolomics Study of the Effects of EGCG on A549 Cells
(−)-Epigallocatechin-3-gallate (EGCG) is the main bioactive catechin in green tea. The antitumor activity of EGCG has been confirmed in various types of cancer, including lung cancer. However, the precise underlying mechanisms are still largely unclear. In the present study, we investigated the metabolite changes in A549 cells induced by EGCG in vitro utilizing liquid chromatography-mass spectrometry (LC-MS)-based metabolomics. The result revealed 33 differentially expressed metabolites between untreated and 80 μM EGCG-treated A549 cells. The altered metabolites were involved in the metabolism of glucose, amino acid, nucleotide, glutathione, and vitamin. Two markedly altered pathways, including glycine, serine and threonine metabolism and alanine, aspartate and glutamate metabolism, were identified by MetaboAnalyst 5.0 metabolic pathway analysis. These results may provide potential clues for the intramolecular mechanisms of EGCG’s effect on A549 cells. Our study may contribute to future molecular mechanistic studies of EGCG and the therapeutic application of EGCG in cancer management.